The Total number of records shown on this page is 100. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
OV_480	Adenovirus	CRAd-IL24 (Ad5/3Δ24cmvIL24)	DNA	Adenoviridae	Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).	No	Viral starin in combination with ING4	IL-24 gene incorporated in place of the deleted E3B region	ATCC	Human ovary cancer cell line	SKOV3ip.1 OvCa	3.0E+5 to 5.0E+5 cells per well	Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	MTS-based Cell Proliferation Assay (Promega)	11 MOI	19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	No	No	NA	No response	NA	NA	NA	NA	27349517
OV_481	Adenovirus	CRAd-IL24 (Ad5/3Δ24cmvIL24)	DNA	Adenoviridae	Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).	No	Viral starin in combination with ING4	IL-24 gene incorporated in place of the deleted E3B region	ATCC	Human ovary cancer cell line	SKOV3luc OvCa	3.0E+5 to 5.0E+5 cells per well	Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	MTS-based Cell Proliferation Assay (Promega)	11 MOI	18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	No	No	NA	No response	NA	NA	NA	NA	27349517
OV_482	Adenovirus	CRAd-IL24 (Ad5/3Δ24cmvIL24)	DNA	Adenoviridae	Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).	No	Viral starin in combination with ING4	IL-24 gene incorporated in place of the deleted E3B region	ATCC	Human ovary cancer cell line	SKOV3ip.1 OvCa	3.0E+5 to 5.0E+5 cells per well	Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	MTS-based Cell Proliferation Assay (Promega)	33 MOI	18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	No	No	NA	No response	NA	NA	NA	NA	27349517
OV_483	Adenovirus	CRAd-IL24 (Ad5/3Δ24cmvIL24)	DNA	Adenoviridae	Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).	No	Viral starin in combination with ING4	IL-24 gene incorporated in place of the deleted E3B region	ATCC	Human ovary cancer cell line	SKOV3luc OvCa	3.0E+5 to 5.0E+5 cells per well	Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	MTS-based Cell Proliferation Assay (Promega)	33 MOI	16% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	No	No	NA	No response	NA	NA	NA	NA	27349517
OV_484	Adenovirus	CRAd-IL24 (Ad5/3Δ24cmvIL24)	DNA	Adenoviridae	Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).	No	Viral starin in combination with ING4	IL-24 gene incorporated in place of the deleted E3B region	ATCC	Human ovary cancer cell line	SKOV3ip.1 OvCa	3.0E+5 to 5.0E+5 cells per well	Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	MTS-based Cell Proliferation Assay (Promega)	100 MOI	14% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	No	No	NA	No response	NA	NA	NA	NA	27349517
OV_485	Adenovirus	CRAd-IL24 (Ad5/3Δ24cmvIL24)	DNA	Adenoviridae	Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).	No	Viral starin in combination with ING4	IL-24 gene incorporated in place of the deleted E3B region	ATCC	Human ovary cancer cell line	SKOV3luc OvCa	3.0E+5 to 5.0E+5 cells per well	Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	MTS-based Cell Proliferation Assay (Promega)	100 MOI	14% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	No	No	NA	No response	NA	NA	NA	NA	27349517
OV_486	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	1 MOI	90% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_487	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	102% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_488	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	108% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_489	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	1 MOI	98% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_490	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	5 MOI	76% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_491	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	98% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_492	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	102% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_493	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	5 MOI	85% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_494	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	10 MOI	58% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_495	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	96% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_496	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	100% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_497	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	10 MOI	96% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_498	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	50 MOI	20% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_499	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	80% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_500	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	37% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_501	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	50 MOI	78% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_502	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	100 MOI	10% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_503	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	56% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_504	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	12% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_505	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	100 MOI	60% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_506	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	1 MOI	98% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_507	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	99% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_508	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	92% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_509	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	1 MOI	90% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_510	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	5 MOI	76% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_511	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	84% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_512	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	73% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_513	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	5 MOI	88% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_514	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	10 MOI	50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_515	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	65% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_516	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_517	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	10 MOI	70% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_518	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	50 MOI	30% cancer cell viability (calculated as relative to mock-infected group), antagonist effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_519	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_520	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_521	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	50 MOI	50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_522	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	100 MOI	16% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_523	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	36% cancer cell viability (calculated as relative to mock-infected group), antagonist effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_524	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	10% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_525	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	100 MOI	32% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_526	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	1 MOI	78% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_527	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	83% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_528	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	79% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_529	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	1 MOI	66% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_530	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	5 MOI	62% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_531	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	77% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_532	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	69% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_533	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	5 MOI	58% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_534	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	10 MOI	44% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_535	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	60% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_536	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_537	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	10 MOI	50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_538	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	50 MOI	30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_539	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	45% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_540	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_541	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	50 MOI	38% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_542	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	100 MOI	12% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_543	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	35% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_544	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	12% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_545	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	100 MOI	23% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_546	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	1 MOI	50% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_547	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	65% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_548	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	50% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_549	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	1 MOI	16% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_550	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	5 MOI	42% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_551	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	60% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_552	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	44% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_553	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	5 MOI	16% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_554	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	10 MOI	30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_555	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_556	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_557	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	10 MOI	16% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_558	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	50 MOI	21% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_559	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	38% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_560	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	22% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_561	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	50 MOI	16% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_562	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	100 MOI	10% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_563	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	25% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_564	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	10% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_565	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	ATCC	Human osteosarcoma cell line	143-B	1.0E+3 cells per well	NA	XTT assay	100 MOI	12% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_566	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	NA	NA	NA	NA	NA	NA	NA	NA	Female BALB/c nu/nu mice inoculated subcutaneously with MNNG/HOS-Luc cells (5.0E+6 cells per site)	5.0E+7 PFU	NA	Proliferating tumor cells expressing ki67 get reduced from 550 cells to 250 cells	Direct injection	NA	NA	NA	27356624
OV_567	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 4 mg/kg body weight ) and doxorubicin (DOX, 2 mg/kg body weight )[drugs were given intraperitoneally]	No	NA	NA	NA	NA	NA	NA	NA	NA	Female BALB/c nu/nu mice inoculated subcutaneously with MNNG/HOS-Luc cells (5.0E+6 cells per site)	5.0E+7 PFU	NA	Proliferating tumor cells expressing ki67 get reduced from 550 cells to 75 cells	Direct injection	NA	NA	NA	27356624
OV_606	Adenovirus	CRAd-CCL21-IL15	DNA	Adenoviridae	Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Yes	No	IL-15	Key Laboratory of Zoonosis, Jilin University	Human prostate cancer cell line	PC-3M	1.0E+5 cells per well	NA	MTT assay	0.1 MOI	70% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	27380620
OV_607	Adenovirus	CRAd-CCL21-IL15	DNA	Adenoviridae	Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Yes	No	IL-15	ATCC	Human cervical cancer cell	HeLa	1.0E+5 cells per well	NA	MTT assay	0.1 MOI	85% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	27380620
OV_608	Adenovirus	CRAd-CCL21-IL15	DNA	Adenoviridae	Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Yes	No	IL-15	ATCC	Human bone osteosarcoma epithelial cell line	U2OS (telomerase-negative)	1.0E+5 cells per well	NA	MTT assay	0.1 MOI	96% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	27380620
OV_609	Adenovirus	CRAd-CCL21-IL15	DNA	Adenoviridae	Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Yes	No	IL-15	Key Laboratory of Zoonosis, Jilin University	Human prostate cancer cell line	PC-3M	1.0E+5 cells per well	NA	MTT assay	1 MOI	40% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	27380620
OV_610	Adenovirus	CRAd-CCL21-IL15	DNA	Adenoviridae	Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Yes	No	IL-15	ATCC	Human cervical cancer cell	HeLa	1.0E+5 cells per well	NA	MTT assay	1 MOI	37% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	27380620
OV_611	Adenovirus	CRAd-CCL21-IL15	DNA	Adenoviridae	Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Yes	No	IL-15	ATCC	Human bone osteosarcoma epithelial cell line	U2OS (telomerase-negative)	1.0E+5 cells per well	NA	MTT assay	1 MOI	94% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	27380620
OV_612	Adenovirus	CRAd-CCL21-IL15	DNA	Adenoviridae	Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Yes	No	IL-15	Key Laboratory of Zoonosis, Jilin University	Human prostate cancer cell line	PC-3M	1.0E+5 cells per well	NA	MTT assay	10 MOI	18% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	27380620
OV_613	Adenovirus	CRAd-CCL21-IL15	DNA	Adenoviridae	Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Yes	No	IL-15	ATCC	Human cervical cancer cell	HeLa	1.0E+5 cells per well	NA	MTT assay	10 MOI	8% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	27380620
OV_614	Adenovirus	CRAd-CCL21-IL15	DNA	Adenoviridae	Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Yes	No	IL-15	ATCC	Human bone osteosarcoma epithelial cell line	U2OS (telomerase-negative)	1.0E+5 cells per well	NA	MTT assay	10 MOI	92% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	27380620
OV_615	Adenovirus	CRAd-CCL21-IL15	DNA	Adenoviridae	Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Yes	No	IL-15	Key Laboratory of Zoonosis, Jilin University	Human prostate cancer cell line	PC-3M	1.0E+5 cells per well	NA	MTT assay	50 MOI	10% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	27380620
OV_616	Adenovirus	CRAd-CCL21-IL15	DNA	Adenoviridae	Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Yes	No	IL-15	ATCC	Human cervical cancer cell	HeLa	1.0E+5 cells per well	NA	MTT assay	50 MOI	5% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	27380620
OV_617	Adenovirus	CRAd-CCL21-IL15	DNA	Adenoviridae	Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Yes	No	IL-15	ATCC	Human bone osteosarcoma epithelial cell line	U2OS (telomerase-negative)	1.0E+5 cells per well	NA	MTT assay	50 MOI	90% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	27380620